Activated thrombin activatable fibrnolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the Athero Gene study - Trégouet, DA; Schnabel, R; Alessi, MC (J Thromb Haemost, 2009)
et al.